loading
전일 마감가:
$13.49
열려 있는:
$13.46
하루 거래량:
62,228
Relative Volume:
0.07
시가총액:
$558.46M
수익:
-
순이익/손실:
$-168.05M
주가수익비율:
-2.654
EPS:
-5.13
순현금흐름:
$-146.15M
1주 성능:
-0.51%
1개월 성능:
-6.73%
6개월 성능:
-20.62%
1년 성능:
-70.74%
1일 변동 폭
Value
$13.42
$13.63
1주일 범위
Value
$13.31
$13.80
52주 변동 폭
Value
$9.12
$72.37

Keros Therapeutics Inc Stock (KROS) Company Profile

Name
명칭
Keros Therapeutics Inc
Name
전화
617-314-6297
Name
주소
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Name
직원
163
Name
트위터
Name
다음 수익 날짜
2024-11-04
Name
최신 SEC 제출 서류
Name
KROS's Discussions on Twitter

KROS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
KROS
Keros Therapeutics Inc
13.62 558.46M 0 -168.05M -146.15M -5.13
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.01 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
512.43 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
310.24 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
536.59 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
255.81 28.51B 3.81B -644.79M -669.77M -6.24

Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-06-10 다운그레이드 BofA Securities Buy → Neutral
2025-01-21 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2025-01-17 다운그레이드 Wedbush Outperform → Neutral
2024-12-16 다운그레이드 Guggenheim Buy → Neutral
2024-12-16 재확인 Oppenheimer Outperform
2024-12-13 재확인 H.C. Wainwright Buy
2024-12-12 다운그레이드 BTIG Research Buy → Neutral
2024-12-12 다운그레이드 TD Cowen Buy → Hold
2024-12-12 다운그레이드 William Blair Outperform → Mkt Perform
2024-11-05 개시 Jefferies Buy
2024-10-24 개시 Cantor Fitzgerald Overweight
2024-10-16 개시 Scotiabank Sector Outperform
2024-09-23 개시 Guggenheim Buy
2024-06-25 개시 Oppenheimer Outperform
2024-02-21 개시 William Blair Outperform
2023-12-08 개시 Wells Fargo Overweight
2023-07-31 개시 Wedbush Outperform
2023-07-26 개시 BofA Securities Buy
2023-02-14 개시 Cowen Outperform
2022-10-18 개시 Truist Buy
2022-07-26 개시 BTIG Research Buy
2020-12-08 재확인 H.C. Wainwright Buy
2020-05-04 개시 H.C. Wainwright Buy
2020-05-04 개시 Jefferies Buy
2020-05-04 개시 Piper Sandler Overweight
2020-05-04 개시 SVB Leerink Outperform
모두보기

Keros Therapeutics Inc 주식(KROS)의 최신 뉴스

pulisher
Jun 18, 2025

(KROS) Trading Report - news.stocktradersdaily.com

Jun 18, 2025
pulisher
Jun 17, 2025

Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - MSN

Jun 17, 2025
pulisher
Jun 16, 2025

Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace

Jun 16, 2025
pulisher
Jun 14, 2025

Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $30.56 - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

Bank of America Downgrades Keros Therapeutics (NASDAQ:KROS) to Neutral - MarketBeat

Jun 13, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Buys 23,342 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Jun 13, 2025
pulisher
Jun 12, 2025

Keros Therapeutics (NASDAQ:KROS) Shares Gap DownTime to Sell? - MarketBeat

Jun 12, 2025
pulisher
Jun 11, 2025

Keros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by Bank of America - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst - Benzinga

Jun 10, 2025
pulisher
Jun 10, 2025

Keros Therapeutics Hindered by KER-065 Concerns Despite 'Intriguing' Pipeline, BofA Says - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

BofA Securities Downgrades Keros Therapeutics to Neutral From Buy, Adjusts Price Target to $18 From $32 - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

KROS: Keros Therapeutics Receives Downgrade from B of A Securities | KROS Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Keros Therapeutics (KROS) Downgraded to Neutral by BofA Analyst - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Keros Therapeutics (KROS) Downgraded to Neutral by BofA Analyst | KROS Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

ADAR1 Demands Bigger Payouts From Keros Therapeutics - Finimize

Jun 10, 2025
pulisher
Jun 09, 2025

Keros Therapeutics to return $375 million to shareholders By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

ADAR1 Capital Management Calls For Keros Therapeutics To Return $475 Mln To Stockholders By Q3 - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Directors Face Massive Shareholder Revolt: ADAR1 Pushes for $475M Dividend and Board Overhaul - Stock Titan

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Therapeutics (KROS) to Return $375M Capital to Shareholders | KROS Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Therapeutics Concludes Strategic Alternatives Review - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Keros to Return $375 Million to Shareholders Following Strategic Review - marketscreener.com

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Announces Return of $375 Million in Excess Capital to Stockholders - The Manila Times

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Therapeutics to return $375 million to shareholders - Investing.com

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Therapeutics Announces $375 Million Capital Return Plan Following Strategic Review - Nasdaq

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Concludes Strategic Review: Massive $375M Shareholder Return While Advancing DMD Drug Development - Stock Titan

Jun 09, 2025
pulisher
Jun 09, 2025

Nuveen Asset Management LLC Sells 181,863 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Wellington Management Group LLP - Defense World

Jun 09, 2025
pulisher
Jun 09, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Position Boosted by Two Sigma Investments LP - Defense World

Jun 09, 2025
pulisher
Jun 06, 2025

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire

Jun 06, 2025
pulisher
Jun 06, 2025

Keros Therapeutics CEO Showcases Breakthrough TGF-ß Platform at Major Goldman Sachs Healthcare Event - Stock Titan

Jun 06, 2025
pulisher
Jun 06, 2025

Two Sigma Advisers LP Has $328,000 Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Nuveen Asset Management LLC Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Jun 05, 2025
pulisher
Jun 03, 2025

Keros Therapeutics (NASDAQ:KROS) Receives Neutral Rating from Wedbush - MarketBeat

Jun 03, 2025
pulisher
Jun 02, 2025

Keros Therapeutics (NASDAQ:KROS) Stock Price Down 3.9%Should You Sell? - MarketBeat

Jun 02, 2025
pulisher
Jun 02, 2025

ProShare Advisors LLC Purchases 2,764 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Bank of America Corp DE - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

D. E. Shaw & Co. Inc. Cuts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

Jun 01, 2025
pulisher
Jun 01, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,386 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Deutsche Bank AG Raises Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

May 31, 2025
pulisher
May 30, 2025

KROS: Wedbush Reiterates Neutral Rating on Keros Therapeutics | - GuruFocus

May 30, 2025
pulisher
May 30, 2025

KROS: Wedbush Reiterates Neutral Rating on Keros Therapeutics | KROS Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

TFG Asset Management GP Ltd Acquires New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat

May 30, 2025
pulisher
May 30, 2025

Keros Therapeutics halts PAH drug development, cuts workforce By Investing.com - Investing.com South Africa

May 30, 2025

Keros Therapeutics Inc (KROS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Keros Therapeutics Inc 주식 (KROS) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Seehra Jasbir
CHIEF EXECUTIVE OFFICER
Apr 04 '25
Option Exercise
0.30
49,367
14,810
302,223
GORDON CARL L
Director
Aug 13 '24
Sale
44.01
250,000
11,002,500
119,522
ORBIMED ADVISORS LLC
Director
Aug 13 '24
Sale
44.01
250,000
11,002,500
119,522
$20.89
price down icon 0.66%
$35.12
price up icon 1.05%
$20.60
price up icon 1.48%
$102.01
price down icon 1.01%
$105.16
price down icon 1.24%
biotechnology ONC
$258.31
price up icon 6.02%
자본화:     |  볼륨(24시간):